Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.

European urology·2026
Same author

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer.

European urology·2026
Same author

Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320).

JAMA oncology·2026
Same author

PSA persistence in the PSMA PET era: reassessing a risk factor after radical prostatectomy.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

On the shape of the radiation survival curve in tumor spheroids: The role of oxygen heterogeneity.

Medical physics·2026
Same author

[Early detection of prostate cancer-recommendations of the updated S3 guideline 2025].

Urologie (Heidelberg, Germany)·2026

Related Experiment Video

Updated: May 28, 2026

Detecting Anastasis In Vivo by CaspaseTracker Biosensor
20:16

Detecting Anastasis In Vivo by CaspaseTracker Biosensor

Published on: February 1, 2018

Second cancer after radiotherapy, 1981-2007.

Detlef Bartkowiak1, Nicole Humble, Peter Suhr

  • 1Department of Radiation Oncology, University Hospital Ulm, Germany. detlef.bartkowiak@uniklinik-ulm.de

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|October 14, 2011
PubMed
Summary

Radiotherapy survivors face a ~1% annual risk of secondary cancers, with contralateral breast cancer being most common. Higher doses may increase risks for head and neck and esophageal cancers.

Related Experiment Videos

Last Updated: May 28, 2026

Detecting Anastasis In Vivo by CaspaseTracker Biosensor
20:16

Detecting Anastasis In Vivo by CaspaseTracker Biosensor

Published on: February 1, 2018

Area of Science:

  • Oncology
  • Radiation Oncology
  • Cancer Epidemiology

Background:

  • Growing concern exists regarding secondary malignancies induced by radiotherapy.
  • Assessing the incidence and dose dependence of second cancers is crucial for patient safety.

Purpose of the Study:

  • To analyze the incidence and dose-response relationship of secondary cancers following radiotherapy.
  • To identify specific cancer types with increased risk after radiation treatment.

Main Methods:

  • Analysis of 12,000 one-year radiotherapy survivors treated between 1981 and 2007.
  • Utilized a German public cancer databank for risk estimates and retrospective dosimetry.
  • Examined contralateral breast, esophageal, and colorectal cancers, incorporating gastrointestinal tract data for risk modeling.

Main Results:

  • The incidence rate of second cancers was approximately 1% per year (493 cases).
  • Contralateral breast cancer showed the highest relative risk (RR=2.8).
  • Increased risks were observed for second head and neck cancer (RR=5.1) and male esophageal cancer (RR=5.8), with dose-response modeling indicating peak induction at 1-5 Gy.

Conclusions:

  • Long-term follow-up is essential for accurate assessment of second cancer risk after radiotherapy.
  • Preliminary modeling suggests potential increased risk from multiportal radiotherapy techniques.
  • Recommendations include prospective out-of-field dosimetry and long-term multicenter data collection to enhance risk assessment.